Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNITE ovarian cancer trial of adavosertib or ceralasertib monotherapy
ACTRN12619001185156Phase 2Active, not recruiting
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of adavosertib and ceralasertib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 cohorts), sponsored by Australia New Zealand Gynaecological Oncology Group. Primary endpoints: Clinical benefit rate and Overall response rate for ceralasertib cohort. Started Mar 2020; status: active, not recruiting.
02
Drugs
adavosertibceralasertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12619001185156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001185156.